With a price-to-earnings (or "P/E") ratio of 75.8x Byotrol plc (LON:BYOT) may be sending very bearish signals at the moment, given that almost half of all companies in the United Kingdom have P/E ratios under 20x and even P/E's lower than 12x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.
With only a limited decrease in earnings compared to most other companies of late, Byotrol has been doing relatively well. The P/E is probably high because investors think this comparatively better earnings performance will continue. If not, then existing shareholders might be a little nervous about the viability of the share price, especially if earnings continue to dissolve.
See our latest analysis for Byotrol
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Byotrol.Is There Enough Growth For Byotrol?
There's an inherent assumption that a company should far outperform the market for P/E ratios like Byotrol's to be considered reasonable.
Retrospectively, the last year delivered a frustrating 8.1% decrease to the company's bottom line. Unfortunately, that's brought it right back to where it started three years ago with EPS growth being virtually non-existent overall during that time. Accordingly, shareholders probably wouldn't have been overly satisfied with the unstable medium-term growth rates.
Shifting to the future, estimates from the only analyst covering the company suggest earnings should grow by 159% over the next year. Meanwhile, the rest of the market is forecast to only expand by 15%, which is noticeably less attractive.
With this information, we can see why Byotrol is trading at such a high P/E compared to the market. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.
The Final Word
We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.
As we suspected, our examination of Byotrol's analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.
Plus, you should also learn about these 4 warning signs we've spotted with Byotrol (including 1 which makes us a bit uncomfortable).
If these risks are making you reconsider your opinion on Byotrol, explore our interactive list of high quality stocks to get an idea of what else is out there.
When trading Byotrol or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
Valuation is complex, but we're here to simplify it.
Discover if Byotrol might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisThis article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
About AIM:BYOT
Byotrol
Develops and commercialize antimicrobial technologies and products in the United Kingdom, North America, and internationally.
Excellent balance sheet and slightly overvalued.